Format

Send to

Choose Destination
Int J Lab Hematol. 2015 May;37 Suppl 1:92-8. doi: 10.1111/ijlh.12358.

Hepcidin and iron disorders: new biology and clinical approaches.

Author information

1
Graduate Program in Areas of Basic and Applied Biology, Abel Salazar Biomedical Sciences Institute, University of Porto, Porto, Portugal.
2
David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, USA.

Abstract

Hepatic hormone hepcidin is a principal regulator of iron homeostasis and a pathogenic factor in common iron disorders. Hepcidin deficiency causes iron overload in hereditary hemochromatosis and iron-loading anemias, whereas hepcidin excess causes or contributes to the development of iron-restricted anemia in inflammatory diseases, infections, some cancers, and chronic kidney disease. Because of this, hepcidin may become a useful tool for diagnosis and management of iron disorders. Furthermore, a number of strategies that target hepcidin, its receptor, and its regulators are under development as novel therapeutic approaches for diseases associated with iron dysregulation.

KEYWORDS:

Hepcidin; anemia; ferroportin; iron; iron overload

PMID:
25976966
DOI:
10.1111/ijlh.12358
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center